Rituximab and multiple sclerosis

Clinical Neuropharmacology

Volumn 35, Issue 2, 2012, Pages 90-96

  Kitsos, Dimitrios K ^a   Tsiodras, Sotirios ^a   Stamboulis, Eleftherios ^a   Voumvourakis, Konstantine I ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Blymphocytes; central nervous system; MS; rituximab

Indexed keywords

BETA1 INTERFERON; CORTICOSTEROID; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB;

AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; INFECTION; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; PATHOGENESIS; PRIORITY JOURNAL; RADIOLOGY; REVIEW;

EID: 84858780351     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824523c9     Document Type: Review

References (50)

1. Owens GP, Bennett JL, Gilden DH, et al. The B cell response in multiple sclerosis. Neurol Res 2006;28(3):236-244. (Pubitemid 43765106)
2. Hasler P, Zouali M. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opin Ther Targets 2006;10(6):803-815. (Pubitemid 44816745)
3. Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 2006;5(7): 564-576. (Pubitemid 43971191)
4. Villar LM, Saádaba MC, Roldan E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005;115(1):187-194. (Pubitemid 40385520)
5. Esiri MM. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977;2(8036):478.
6. Alter A, Duddy M, Hebert S, et al. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003;170(9): 4497-4505. (Pubitemid 36522744)
7. Ray A, Mann MK, Basu S, et al. A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol 2011;230(1-2):1-9.
8. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47(6):707-717. (Pubitemid 30390191)
9. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59(6):880-892. (Pubitemid 43830920)
10. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006;24:467-496.
11. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 1990;8:773-793. (Pubitemid 20135646)
12. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004;172(6):3422-3427 (Pubitemid 38337921)
13. Lund FE, Garvy BA, Randall TD, et al. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005;8:25-54.
14. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14(2): 164-174. (Pubitemid 38656388)
15. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130(Pt 4): 1089-1104. (Pubitemid 47355604)
16. Edwards JC, Cambridge G. Prospects for B-cellYtargeted therapy in autoimmune disease. Rheumatology (Oxford) 2005;44(2):151-156. (Pubitemid 40277394)
17. Jiang H, Milo R, Swoveland P, et al. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 1995;61(1):17-25.
18. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997;99(11):2664-2671. (Pubitemid 27259813)
19. Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001;112(1-2):153-162.
20. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004;172(11):7144-7153. (Pubitemid 38669158)
21. Chan A, Weilbach FX, Toyka KV, et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139(1):152-158. (Pubitemid 40066141)
22. Humle Jorgensen S, Sorensen PS. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. J Neurol Sci 2005;233(1-2):61-65. (Pubitemid 40804817)
23. Stangel M, Toyka KV, Gold R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 1999;56(6):661-663. (Pubitemid 29266463)
24. Warren KG, Catz I, Jeffrey VM, et al. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci 1986;13(1):25-30. (Pubitemid 16189885)
25. Frequin ST, Barkhof F, Lamers KJ, et al. CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 1992;86(3):291-297.
26. Frequin ST, Barkhof F, Lamers KJ, et al. Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis. Mult Scler 1995;1(1):20-24.
27. Niino M, Bodner C, Simard ML, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006;59(5):748-754. (Pubitemid 43673152)
28. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15(9):450-454. (Pubitemid 24272191)
29. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;4(10):557-567.
30. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008;70(23):2252-2260.
31. Peter HH, Warnatz K. Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity. Expert Opin Biol Ther 2005;5(suppl 1):S61-S71. (Pubitemid 41243346)
32. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201(2):195-200. (Pubitemid 40189428)
33. Dillon SR, Gross JA, Ansell SM, et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5(3):235-246. (Pubitemid 43336036)
34. Thangarajh M, Masterman T, Rot U, et al. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 2005;167(1-2):210-214. (Pubitemid 41242304)
35. Huntington ND, Tomioka R, Clavarino C, et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 2006;18(10):1473-1485. (Pubitemid 44446825)
36. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-446. (Pubitemid 30208162)
37. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001;2(1):147-153. (Pubitemid 33741968)
38. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 Pt 1): 859-866. (Pubitemid 44356635)
39. Edwards JC, Cambridge G, Abraham VM. Do self-perpetuating B lymphocytes drive human autoimmune disease. Immunology 1999;97(2):188-196. (Pubitemid 29274149)
40. Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis 2005;64(Suppl 4): iv77-iv80 (Pubitemid 41532025)
41. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90(6):2188-2195. (Pubitemid 27392702)
42. Alwayn IP, Xu Y, Basker M, et al. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22- positive B cells does not result in decreased production of anti-alphaGal antibody. Xenotransplantation 2001;(3):157-171. (Pubitemid 32655981)
43. Raju R, Dalakas M. The clinical response of rituximab with anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP) is associated with alteration of lymphocyte homing and induction of regulatory T cells. Ann Neurol 2006;(Suppl 60, 95).
44. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab antiYB-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17(5):550-557. (Pubitemid 41527814)
45. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357(19):1903-1915. (Pubitemid 350074686)
46. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5(2):170-175. (Pubitemid 29068523)
47. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005;128(Pt 7):1667-1676. (Pubitemid 41373685)
48. Frohman EM, Racke MK, Raine CS. Multiple sclerosisVthe plaque and its pathogenesis. N Engl J Med 2006;354(9):942-955.
49. Hedegaard CJ, Sellebjerg F, Krakauer M, et al. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler 2011;17(5):567-577.
50. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010;74(23):1860-1867.
51. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010;67(6):707-714.
52. Karenfort M, Kieseier BC, Tibussek D, et al. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol 2009;51(2):159-161
53. Stuve O, Leussink VI, Frohlich R, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009;66(2):259-261
54. Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66(4):460-471
55. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63(3):395-400
56. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-688
57. Petereit HF, Moeller-Hartmann W, Reske D, et al. Rituximab in a patient with multiple sclerosisVeffect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008;117(6):399-403.
58. Benedetti L, Franciotta D, Vigo T, et al. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. Arch Neurol 2007;64(10):1531-1533
59. Leussink VI, Lehmann HC, Meyer zu Horste G, et al. Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity. J Neurol 2008;255(9):1436-1438.
60. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.J Neuroimmunol 2006;180(1-2):63-70
61. Monson NL, Cravens PD, Frohman EM, et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients wit primary progressive multiple sclerosis. Arch Neurol 2005;62(2):258-264
62. Stuve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005;62(10):1620-1623